Brain gene therapy tested for Parkinson's
NCT ID NCT01621581
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 6 times
Summary
This early-phase study tested a gene therapy that delivers a protective protein (GDNF) directly to the brain in 25 people with advanced Parkinson's disease. The goal was to see if it is safe and to gather early information on whether it might help protect dopamine-producing brain cells. Participants received a one-time infusion during brain surgery and were followed for up to 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Can brain stimulation sharpen Decision-Making in Parkinson's?
- Can Stem-Cell implants restore movement in Parkinson's?
- Wild blueberries put to the test for Parkinson's motor symptoms
- Could tailored brain stimulation quiet Parkinson's tremors more effectively?
- Zapping away tremors: scientists probe how electrical stimulation calms shaky hands